Business
AXIM Biotechnologies, Inc. Announces Exclusive Distribution Agreement With VisionPlus Corp. for TearScan(R) Lactoferrin and IgE Diagnostic Tests in South Korea
AXIM Biotechnologies, Inc. Announces Exclusive Distribution Agreement With VisionPlus Corp. for TearScan(R) Lactoferrin and IgE Diagnostic Tests in South Korea.
About this update from Axim Biotechnologies, Inc.
[{"type":"text","content":"\r\n\r\n \r\n \r\n AXIM Biotechnologies, Inc. Announces Exclusive Distribution Agreement With VisionPlus Corp. for TearScan(R) Lactoferrin and IgE Diagnostic Tests in South Korea\r\n \r\n \r\n\r\n\r\nAXIM Biotechnologies, Inc. Announces Exclusive Distribution Agreement With VisionPlus Corp. for TearScan(R) Lactoferrin and IgE Diagnostic Tests in South Korea\r\n\r\n\r\n\r\n\r\n\r\nSAN DIEGO, CA - October 23, 2025 (NEWMEDIAWIRE) - AXIM Biotechnologies, Inc. (OTC:AXIM) (\"AXIM\"), a leader in rapid, point-of-care ocular diagnostics, today announced it has entered into an exclusive distribution agreement with VisionPlus Corp. (\"VisionPlus\") to market and distribute AXIM's TearScan® Lactoferrin Test for the detection of aqueous-deficient dry eye (ADDE) and TearScan® IgE Test for ocular allergy throughout South Korea.\r\nUnder the agreement, VisionPlus receives exclusive rights to distribute AXIM's TearScan® Lactoferrin and TearScan® IgE diagnostic tests, both supported by the I-Peak digital reader, across South Korea. The companies will collaborate on Korean MFDS registration, targeting simultaneous submissions for both assays. VisionPlus will lead local compliance, regulatory coordination, and commercialization through its established network of ophthalmology clinics, hospitals, and specialty Dry Eye Centers.\r\nThe initial term of the agreement is one year, with automatic one-year renewals for an additional four years tied to annual sales milestones. AXIM will retain manufacturing control, intellectual-property ownership, and provide regulatory and technical support for market entry and ongoing product quality compliance.\r\nCatalina Valencia, President of AXIM Biotechnologies, stated:\"VisionPlus is an exceptional partner with a proven commitment to advancing ocular health. Their clinical insight and national reach make them ideal to introduce AXIM's TearScan® platform to South Korea. This collaboration will bring quantitative tear diagnostics directly to clinicians, improving diagnostic precision and enabling more personalized care for patients suffering from dry eye disease and ocular allergy.\"\r\nJerry Park, President of VisionPlus Corp., added:\"Years ago, VisionPlus recognized that the global rise in digital device use and worsen...